



Registration of a Charge

Company name: **NOVABIOTICS LIMITED**

Company number: **SC272344**

Received for Electronic Filing: **07/11/2018**



X7I7NEY1

Details of Charge

Date of creation: **02/11/2018**

Charge code: **SC27 2344 0003**

Persons entitled: **BARWELL PLC (AS SECURITY TRUSTEE)**

Brief description: **ALL OF THE COMPANY'S RIGHT, TITLE AND INTEREST IN, TO AND UNDER ITS INTELLECTUAL PROPERTY, AS SPECIFIED IN THE IP SECURITY AGREEMENT REGISTERED BY THIS FORM MR01 (THE "IP SECURITY AGREEMENT"), INCLUDING THOSE PATENTS SET OUT IN SCHEDULE 1 OF THE IP SECURITY AGREEMENT.**

Contains floating charge(s) .

Contains negative pledge.

Authentication of Form

This form was authorised by: **a person with an interest in the registration of the charge.**

Authentication of Instrument

Certification statement: **I CERTIFY THAT SAVE FOR MATERIAL REDACTED PURSUANT TO S.859G OF THE COMPANIES ACT 2006 THE ELECTRONIC COPY INSTRUMENT DELIVERED AS PART OF THIS APPLICATION**

**FOR REGISTRATION IS A CORRECT COPY OF THE ORIGINAL
INSTRUMENT.**

Certified by:

BEN LAND-MAYCOCK



CERTIFICATE OF THE REGISTRATION OF A CHARGE

Company number: 272344

Charge code: SC27 2344 0003

The Registrar of Companies for Scotland hereby certifies that a charge dated 2nd November 2018 and created by NOVABIOTICS LIMITED was delivered pursuant to Chapter A1 Part 25 of the Companies Act 2006 on 7th November 2018 .

Given at Companies House, Edinburgh on 8th November 2018

The above information was communicated by electronic means and authenticated by the Registrar of Companies under section 1115 of the Companies Act 2006



Companies House



**THE OFFICIAL SEAL OF THE
REGISTRAR OF COMPANIES**

DATED 02 NOVEMBER 2018


NOVABIOTICS LIMITED

-and-

BARWELL PLC

Intellectual Property
Security Agreement

SAVE FOR MATERIAL REDACTED PURSUANT TO S8396
OF THE COMPANIES ACT 2006, I CERTIFY THAT THIS
IS A TRUE COPY OF THE ORIGINAL SEEN BY ME



NAME: BEN LAND-MAHCOLIK

TITLE: SOLICITOR, COVINGTON & BURLING LLP

DATE: 07/11/2018

COVINGTON

COVINGTON & BURLING LLP

TABLE OF CONTENTS

1.	DEFINITIONS AND INTERPRETATION	5
1.1	Definitions	5
1.2	Interpretation.....	7
2.	COVENANT TO PAY.....	8
2.1	Covenant to Pay.....	8
3.	GRANT OF SECURITY	8
3.1	Fixed Charges.....	8
3.2	Floating Charge	8
3.3	Qualifying Floating Charge.....	9
3.4	Automatic Crystallisation of Floating Charge.....	9
3.5	Crystallisation of Floating Charge By Notice.....	9
3.6	Intellectual Property Acquired After Any Floating Charge Has Crystallised	9
3.7	Excluded Assets.....	10
4.	REPRESENTATIONS AND WARRANTIES	10
4.1	Representations and Warranties.....	10
4.2	Chargor	10
4.3	Ownership of Secured Assets	10
4.4	No Security.....	10
4.5	No Adverse Claims.....	10
4.6	No Breach of Laws.....	10
4.7	Times for Making Representations and Warranties.....	11
5.	GENERAL COVENANTS.....	11
5.1	Preservation of Secured Assets.....	11
5.2	Negative Pledge.....	11
5.3	Compliance With Laws and Regulations	11
5.4	Notice of Misrepresentation and Breaches.....	11
5.5	Information	12
6.	REGISTRATION OF INTELLECTUAL PROPERTY	12
7.	POWERS OF THE SECURITY TRUSTEE	12
7.1	Power to Remedy.....	12
7.2	Exercise of Rights	13
7.3	Security Trustee Has Receiver's Powers.....	13
7.4	Indulgence	13

7.5	Appointment of An Administrator.....	13
8.	WHEN SECURITY BECOMES ENFORCEABLE.....	14
8.1	Security Becomes Enforceable on Event of Default.....	14
8.2	Discretion.....	14
9.	ENFORCEMENT OF SECURITY.....	14
9.1	Prior Security.....	14
9.2	Protection of Third Parties.....	14
9.3	Conclusive Discharge to Purchasers.....	15
10.	REC EIVER.....	15
10.1	Appointment.....	15
10.2	Removal.....	15
10.3	Power of Appointment Exercisable Despite Prior Appointments.....	15
10.4	Agent of the Chargor.....	15
11.	POWERS OF REC EIVER.....	16
11.1	General.....	16
11.2	Employ Personnel and Advisors.....	16
11.3	Remuneration.....	16
11.4	Realise Secured Assets.....	16
11.5	Dispose of Secured Assets.....	16
11.6	Valid Receipts.....	17
11.7	Make Settlements.....	17
11.8	Bring Proceedings.....	17
11.9	Insure.....	17
11.10	Redeem Prior Security.....	17
11.11	Delegation.....	17
11.12	Absolute Beneficial Owner.....	17
11.13	Incidental Powers.....	18
12.	DELEGATION.....	18
12.1	Delegation.....	18
12.2	Terms.....	18
12.3	Liability.....	18
13.	APPLICATION OF PROCEEDS.....	18
13.1	Order of Application of Proceeds.....	18
14.	COSTS.....	19
14.1	Costs.....	19
15.	FURTHER ASSURANCE.....	19

15.1	Further Assurance	19
16.	RELEASE	20
17.	ASSIGNMENT AND TRANSFER	20
17.1	Assignment By Security Trustee.....	20
17.2	Assignment By Chargor.....	20
18.	AMENDMENTS, WAIVERS AND CONSENTS	20
18.1	Amendments	20
18.2	Waivers and Consents.....	20
18.3	Rights and Remedies	21
19.	SEVERANCE	21
19.1	Severance.....	21
20.	COUNTERPARTS	21
20.1	Counterparts.....	21
21.	THIRD PARTY RIGHTS	22
21.1	Third Party Rights.....	22
22.	FURTHER PROVISIONS	22
22.1	Independent Security	22
22.2	Continuing Security.....	22
22.3	Certificates.....	22
23.	NOTICES	22
23.1	Delivery.....	22
23.2	Receipt By Chargor and Security Trustee.....	23
23.3	Service of Proceedings.....	23
24.	GOVERNING LAW AND JURISDICTION.....	24
24.1	Governing Law.....	24
24.2	Jurisdiction.....	24
	SCHEDULE 1 - PATENT PORTFOLIO AS AT 21 JUNE 2018.....	25
	SIGNATURE PAGE.....	59

THIS AGREEMENT is made by way of Deed on 02 November 2018

BETWEEN:

1. **NOVABIOTICS LIMITED** (company number SC272344) whose registered office is at Cruickshank Building Craibstone, Bucksburn, Aberdeen, Scotland, AB21 9TR (the “**Chargor**”); and
2. **BARWELL PLC** (company number SC142927) whose registered office is at Sterling House, 20 Renfield Street, Glasgow, G2 5AP as security trustee for the Noteholders pursuant to the terms of the Security Trust Deed (defined below) (the “**Security Trustee**” acting for and on behalf of the Noteholders).

WHEREAS:

- A. The Noteholders are the holders of certain convertible secured loan notes issued by the Chargor pursuant to the terms of the Instrument.
- B. Pursuant to the Security Trust Deed, Barwell Plc has declared that it holds the Transaction Security (as defined in the Security Trust Deed) on trust for the Noteholders on the terms contained in the Security Trust Deed.
- C. The Chargor has agreed, pursuant to the terms of this deed, to provide the Security over its Intellectual Property to the Security Trustee for the convertible loan notes made available under the Instrument.

IT IS AGREED AS FOLLOWS:

1. **DEFINITIONS AND INTERPRETATION**

1.1 **Definitions**

The following definitions apply in this deed:

“**Administrator**” means an administrator appointed to manage the affairs, business and property of the Chargor pursuant to clause 7.5;

“**Business Day**” means a day other than a day which is a Saturday, Sunday or public holiday in England and Scotland;

“Delegate” means any person appointed by the Security Trustee or any Receiver pursuant to clause 12 and any person appointed as attorney of such Security Trustee, Receiver or Delegate;

“Event of Default” has the meaning given to that expression in the Instrument;

“Instrument” means the convertible loan note instrument dated on or around the date hereof issued by the Chargor for the provision of the convertible loan notes secured by this deed;

“Finance Documents” means the Instrument, this deed and any other document or agreement designated as such by the Security Trustee (acting on the instructions of the Lender Majority) and the Chargor;

“Intellectual Property” means, in respect of the Chargor, its present and future patents, trade marks, service marks, trade names, designs, copyrights, inventions, topographical or similar rights, confidential information and identifiable know-how, whether in physical or in electronic form, and any interest in any of these rights, whether or not registered, including all applications and rights to apply for registration and all fees, royalties and other rights derived from, or incidental to, these rights, including the intellectual property specified in schedule 1;

“Lender Majority” has the meaning given to it in the Instrument;

“Receiver” means a receiver, receiver and manager or administrative receiver of any or all of the Secured Assets appointed by the Security Trustee (acting on the instructions of the Lender Majority) under clause 10;

“Secured Assets” means all the Intellectual Property for the time being subject to the Security created by, or pursuant to, this deed;

“Secured Liabilities” means all present and future monies, obligations and liabilities owed by the Chargor to the Noteholders, whether actual or contingent, as principal or surety or in any other capacity, under or in connection with the Instrument or this deed, together with all interest (including, without limitation, default interest) accruing in respect of those monies or liabilities;

“Security” means any mortgage, charge (whether fixed or floating, legal or equitable), pledge, lien, assignment by way of security or other security interest securing any obligation of any person, or any other agreement or arrangement having a similar effect;

“Security Period” means the period starting on the date of this deed and ending on the date on which the Secured Liabilities have been either paid and discharged in full or converted in accordance with the provisions of the Instrument; and

“Security Trust Deed” means the security trust deed dated on or before the date hereof among the Chargor, Barwell Plc and the Initial Noteholders (as referred to therein).

1.2 Interpretation

In this deed:

- (a) clause headings shall not affect the interpretation of this deed;
- (b) a reference to a **“person”** shall include a reference to an individual, firm, company, corporation, partnership, unincorporated body of persons, government, state or agency of a state or any association, trust, joint venture or consortium (whether or not having separate legal personality);
- (c) unless the context otherwise requires, words in the singular shall include the plural and in the plural shall include the singular;
- (d) unless the context otherwise requires, a reference to one gender shall include a reference to the other genders;
- (e) a reference to a party shall include that party’s successors, permitted assigns and permitted transferees;
- (f) a reference to a statute or statutory provision is a reference to it as amended, extended or re-enacted from time to time;
- (g) a reference to a statute or statutory provision shall include all subordinate legislation made from time to time under that statute or statutory provision;
- (h) a reference to **“writing”** or **“written”** includes fax and e-mail;
- (i) an obligation on a party not to do something includes an obligation not to allow that thing to be done;
- (j) a reference to **“this deed”** (or any provision of it) or to any other agreement or document referred to in this deed is a reference to this deed, that provision or such other agreement or document as amended from time to time;
- (k) unless the context otherwise requires, a reference to a clause or a schedule is to a clause of, or a schedule to, this deed;
- (l) any words following the terms **“including”**, **“include”**, **“in particular”**, **“for example”** or any similar expression shall be construed as illustrative and shall not limit the sense of the words, description, definition, phrase or term preceding those terms;

- (m) a reference to an “**amendment**” includes a novation, re-enactment, supplement or variation (and amended shall be construed accordingly);
- (n) a reference to “**assets**” includes present and future properties, undertakings, revenues, rights and benefits of every description;
- (o) a reference to an “**authorisation**” includes an approval, authorisation, consent, exemption, filing, licence, notarisation, registration and resolution;
- (p) a reference to “**continuing**” in relation to an Event of Default means an Event of Default that has not been remedied or waived;
- (q) a reference to “**determines**” or “**determined**” means, unless the contrary is indicated, a determination made at the absolute discretion of the person making it;
- (r) a reference to a “**regulation**” includes any regulation, rule, official directive, request or guideline (whether or not having the force of law) of any governmental, inter-governmental or supranational body, agency, department or regulatory, self-regulatory or other authority or organisation; and
- (s) capitalised terms not otherwise defined herein have the same meaning as given in the Instrument.

2. COVENANT TO PAY

2.1 Covenant to Pay

The Chargor shall, on demand, pay to the Noteholders and discharge the Secured Liabilities when they become due pursuant to the terms of the Instrument.

3. GRANT OF SECURITY

3.1 Fixed Charges

As a continuing security for the payment and discharge of the Secured Liabilities, the Chargor with full title guarantee charges to the Security Trustee by way of first fixed charge, all of its respective Intellectual Property.

3.2 Floating Charge

As a continuing security for the payment and discharge of the Secured Liabilities, the Chargor with full title guarantee charges to the Security Trustee, by way of first floating charge, all its respective Intellectual Property not effectively charged pursuant to clause 3.1.

3.3 Qualifying Floating Charge

Paragraph 14 of Schedule B1 to the Insolvency Act 1986 applies to the floating charge created by clause 3.2.

3.4 Automatic Crystallisation of Floating Charge

The floating charge created by clause 3.2 shall automatically and immediately (without notice) be converted into a fixed charge over the assets subject to that floating charge if:

- (a) the Chargor in question:
 - (i) creates, or attempts to create, without the prior written consent of the Security Trustee (acting on the instructions of the Lender Majority), a Security or a trust in favour of another person over all or any part of the Secured Assets (except as expressly permitted by the terms of this deed or the Instrument); or
 - (ii) disposes, or attempts to dispose of, all or any part of the Secured Assets without the prior written consent of the Lender Majority (other than Secured Assets that are only subject to the floating charge while it remains uncrystallised or which may be disposed of pursuant to clause 5.1);
- (b) any person levies (or attempts to levy) any distress, attachment, execution or other process against all or any part of the Secured Assets; or
- (c) a resolution is passed or an order is made for the winding-up, dissolution, administration or re-organisation of the Chargor.

3.5 Crystallisation of Floating Charge By Notice

The Security Trustee (acting on the instructions of the Lender Majority) may, in its sole discretion, by written notice to the Chargor, convert the floating charge created by the Chargor under this deed into a fixed charge as regards any part of the Secured Assets specified by the Security Trustee (acting on the instructions of the Lender Majority) in that notice if an Event of Default occurs and is continuing.

3.6 Intellectual Property Acquired After Any Floating Charge Has Crystallised

Any Intellectual Property acquired by the Chargor after any crystallisation of the floating charge created under this deed that, but for that crystallisation, would be subject to a floating charge under this deed, shall (unless the Security Trustee (acting on the instructions of the

Lender Majority) confirms otherwise to the Chargor in writing) be charged to the Security Trustee by way of first fixed charge.

3.7 Excluded Assets

Notwithstanding any other provision of this deed, no Security interest of any kind shall be created (whether directly or indirectly) over any assets of the Chargor that are not Intellectual Property.

4. REPRESENTATIONS AND WARRANTIES

4.1 Representations and Warranties

The Chargor makes the representations and warranties set out in this clause 4 to the Security Trustee in respect of itself and those Secured Assets over which it is granting Security pursuant to this deed.

4.2 Chargor

The Chargor is duly incorporated and validly existing under the laws of its place of incorporation; has the power to grant the Security pursuant to this deed; and has taken all necessary corporate actions to authorise the execution and delivery of this deed and the performance of its obligations under this deed.

4.3 Ownership of Secured Assets

The Chargor is the legal and beneficial owner of the Secured Assets.

4.4 No Security

The Secured Assets are free from any Security other than the Security created by this deed.

4.5 No Adverse Claims

The Chargor has not received, or acknowledged notice of, any adverse claim by any person in respect of the Secured Assets or any interest in them.

4.6 No Breach of Laws

So far as the Chargor is aware, there is no breach of any law or regulation that materially and adversely affects the Secured Assets.

4.7 Times for Making Representations and Warranties

The representations and warranties set out in clause 4.2 to clause 4.6 are made by the Chargor on the date of this deed and, save for the representations and warranties set out in clause 4.5, are deemed to be repeated on each day of the Security Period with reference to the facts and circumstances existing at the time of repetition.

5. GENERAL COVENANTS

5.1 Preservation of Secured Assets

The Chargor shall not do, or permit to be done, any act or thing that would, to a material extent, depreciate, jeopardise or otherwise prejudice the Security, or materially diminish the value of any of the Secured Assets or the effectiveness of the Security created by this deed, provided that the Chargor shall not be prohibited from abandoning, cancelling or allowing to lapse any Intellectual Property in the ordinary course of its business or that is no longer materially useful to its business. Notwithstanding the above, or any other provision of this deed, the Chargor is permitted and has full power and authority, without restriction, to continue its business on a day-to-day basis in the manner in which it was conducted prior to entry into the Finance Documents.

5.2 Negative Pledge

During the Security Period, the Chargor shall not at any time, except with the prior written consent of the Security Trustee (acting on the instructions of the Lender Majority) (such consent not to be unreasonably withheld), create, purport to create or permit to subsist any Security on, or in relation to, any Secured Asset other than any Security created by this deed.

5.3 Compliance With Laws and Regulations

- (a) The Chargor shall not, without the prior written consent of the Security Trustee (acting on the instructions of the Lender Majority), use or permit the Secured Assets to be used in any way contrary to law.
- (b) The Chargor shall comply with the requirements of any law and regulation relating to or affecting the Secured Assets or the use of them or any part of them.

5.4 Notice of Misrepresentation and Breaches

The Chargor shall, as soon as reasonably practicable on becoming aware of any of the same, give the Security Trustee notice in writing of:

- (a) any representation or warranty set out in this deed that is incorrect or misleading in any material respect when made or deemed to be repeated; and
- (b) any breach of any covenant set out in this deed.

5.5 Information

The Chargor shall promptly notify the Security Trustee in writing of any action, claim or demand made by or against it in connection with any Secured Asset or of any fact, matter or circumstance which may, with the passage of time, give rise to such an action, claim or demand, in each case that is reasonably likely to have a material adverse effect on such Secured Asset, together with, in each case, the Chargor's proposals for settling, liquidating, compounding or contesting any such action, claim or demand and shall, subject to the Security Trustee's (acting on the instructions of the Lender Majority) prior approval, implement those proposals at its own expense.

6. REGISTRATION OF INTELLECTUAL PROPERTY

- 6.1 The Chargor shall, if requested to do so in writing by the Security Trustee (acting on the instructions of the Lender Majority), make entries in any public register in the United Kingdom and the United States of America of any registered Intellectual Property comprised in the Secured Assets as set out in schedule 1 to this deed, which either record the existence of this deed or the restrictions on disposal imposed by this deed.
- 6.2 The Chargor shall use reasonable endeavours to ensure that the registration of this deed (or the restrictions imposed by this deed) in respect of any registered Intellectual Property set out in schedule 1 to this deed with appropriate public registers as contemplated by clause 6.1, shall have occurred by no later than 120 days after receipt of the written request by the Security Trustee.

7. POWERS OF THE SECURITY TRUSTEE

7.1 Power to Remedy

- (a) The Security Trustee (acting on the instructions of the Lender Majority) shall be entitled (but shall not be obliged) to remedy, at any time, a breach by the Chargor of any of its obligations contained in this deed.
- (b) Any reasonable monetary expenditure by the Security Trustee (acting on the instructions of the Lender Majority) in remedying a breach by the Chargor of its obligations contained in this deed shall be reimbursed by the Chargor to the Security Trustee on a full indemnity basis.

7.2 Exercise of Rights

The rights of the Security Trustee under clause 7.1 are without prejudice to any other rights of the Security Trustee under this deed.

7.3 Security Trustee Has Receiver's Powers

To the extent permitted by law, any right, power or discretion conferred by this deed on a Receiver may, after the security constituted by this deed has become enforceable, be exercised by the Security Trustee (acting on the instructions of the Lender Majority) in relation to any of the Secured Assets whether or not it has taken possession of any Secured Assets and without first appointing a Receiver or notwithstanding the appointment of a Receiver.

7.4 Indulgence

The Security Trustee (acting on the instructions of the Lender Majority) may, at its discretion, grant time or other indulgence, or make any other arrangement, variation or release with any person not being a party to this deed (whether or not any such person is jointly liable with the Chargor) in respect of any of the Secured Liabilities, or of any other security for them without prejudice either to this deed or to the liability of the Chargor for the Secured Liabilities.

7.5 Appointment of An Administrator

- (a) The Security Trustee (acting on the instructions of the Lender Majority) may, without notice to the Chargor, appoint any one or more persons to be an Administrator of the Chargor pursuant to Paragraph 14 of Schedule B1 of the Insolvency Act 1986 if the Security constituted by this deed becomes enforceable.
- (b) Any appointment under this clause 7.5 shall:
 - (i) be in writing signed by a duly authorised signatory of the Security Trustee (acting on the instructions of the Lender Majority); and
 - (ii) take effect, in accordance with paragraph 19 of Schedule B1 of the Insolvency Act 1986.
- (c) The Security Trustee (acting on the instructions of the Lender Majority) may apply to the court for an order removing an Administrator from office and may by notice in writing in accordance with this clause 7.5 appoint a replacement for any Administrator who has died, resigned, been removed or who has vacated office upon ceasing to be qualified.

8. WHEN SECURITY BECOMES ENFORCEABLE

8.1 Security Becomes Enforceable on Event of Default

The Security constituted by this deed shall be immediately enforceable if an Event of Default occurs and is continuing.

8.2 Discretion

After the Security constituted by this deed has become enforceable, the Security Trustee (acting on the instructions of the Lender Majority) may, in its absolute discretion, enforce all or any part of that Security at the times, in the manner and on the terms it thinks fit, and take possession of and hold or dispose of all or any part of the Secured Assets.

9. ENFORCEMENT OF SECURITY

9.1 Prior Security

At any time after the Security constituted by this deed has become enforceable, or after any powers conferred by any Security having priority to this deed shall have become exercisable, the Security Trustee (acting on the instructions of the Lender Majority) may:

- (a) redeem that or any other prior Security;
- (b) procure the transfer of that Security to it; and
- (c) settle and pass any account of the holder of any prior Security.

Any accounts so settled and passed shall be, in the absence of any manifest error, conclusive and binding on the Chargor. All monies paid by the Security Trustee (acting on the instructions of the Lender Majority) to an encumbrancer in settlement of any of those accounts shall, as from their payment by the Security Trustee (acting on the instructions of the Lender Majority), be due from the Chargor to the Security Trustee on current account and shall be secured as part of the Secured Liabilities.

9.2 Protection of Third Parties

No purchaser, mortgagee or other person dealing with the Security Trustee (acting on the instructions of the Lender Majority), any Receiver or Delegate shall be concerned to enquire:

- (a) whether any of the Secured Liabilities have become due or payable, or remain unpaid or undischarged;

- (b) whether any power the Security Trustee (acting on the instructions of the Lender Majority), a Receiver or Delegate is purporting to exercise has become exercisable or is properly exercisable; or
- (c) how any money paid to the Security Trustee (acting on the instructions of the Lender Majority), any Receiver or any Delegate is to be applied.

9.3 Conclusive Discharge to Purchasers

The receipt of the Security Trustee (acting on the instructions of the Lender Majority) or any Receiver or Delegate shall be a conclusive discharge to a purchaser and, in making any sale or other disposal of any of the Secured Assets or in making any acquisition in the exercise of their respective powers, the Security Trustee (acting on the instructions of the Lender Majority), every Receiver and Delegate may do so for any consideration, in any manner and on any terms that it or he thinks fit.

10. RECEIVER

10.1 Appointment

At any time after the Security constituted by this deed has become enforceable, or at the request of the Chargor, the Security Trustee (acting on the instructions of the Lender Majority) may, without further notice, appoint by way of deed, or otherwise in writing, any one or more persons to be a Receiver of all or any part of the Secured Assets.

10.2 Removal

The Security Trustee (acting on the instructions of the Lender Majority) may, without further notice (subject to section 45 of the Insolvency Act 1986), from time to time, by way of deed, or otherwise in writing, remove any Receiver appointed by it and may, whenever it thinks fit, appoint a new Receiver in the place of any Receiver whose appointment may for any reason have terminated.

10.3 Power of Appointment Exercisable Despite Prior Appointments

The power to appoint a Receiver (whether conferred by this deed or by statute) shall be, and remain, exercisable by the Security Trustee (acting on the instructions of the Lender Majority) despite any prior appointment in respect of all or any part of the Secured Assets.

10.4 Agent of the Chargor

Any Receiver appointed by the Security Trustee (acting on the instructions of the Lender Majority) under this deed shall be the agent of the Chargor and the Chargor shall be solely

responsible for the contracts, engagements, acts, omissions, defaults, losses and remuneration of that Receiver and for liabilities incurred by that Receiver. The agency of each Receiver shall continue until the Chargor goes into liquidation and after that the Receiver shall act as principal and shall not become the agent of the Security Trustee.

11. POWERS OF RECEIVER

11.1 General

- (a) Any Receiver appointed by the Security Trustee (acting on the instructions of the Lender Majority) under this deed shall, in addition to the powers conferred on him by statute, have the powers set out in clause 11.2 to clause 11.13.
- (b) If there is more than one Receiver holding office at the same time, each Receiver may (unless the document appointing him states otherwise) exercise all of the powers conferred on a Receiver under this deed individually and to the exclusion of any other Receiver.
- (c) Any exercise by a Receiver of any of the powers given by clause 11 may be on behalf of the Chargor, or himself.

11.2 Employ Personnel and Advisors

A Receiver may provide services and employ, or engage any managers, officers, servants, contractors, workmen, agents, other personnel and professional advisers on any terms, and subject to any conditions, that he, acting reasonably, thinks fit. A Receiver may discharge any such person or any such person appointed by the Chargor.

11.3 Remuneration

A Receiver may charge and receive any reasonable sum by way of remuneration (in addition to all costs, charges and expenses incurred by him) that the Security Trustee (acting on the instructions of the Lender Majority) may prescribe or agree with him.

11.4 Realise Secured Assets

A Receiver may collect and get in the Secured Assets or any part of them in respect of which he is appointed, and make any demands and take any proceedings as may seem expedient for that purpose, and take possession of the Secured Assets with like rights.

11.5 Dispose of Secured Assets

A Receiver may sell, exchange, convert into money and realise all or any of the Secured Assets in respect of which he is appointed in any manner (including, without limitation, by public auction or private sale) and generally on any terms and conditions as he thinks fit. Any sale may be for any consideration that the Receiver thinks fit and a Receiver may promote, or concur in promoting, a company to purchase the Secured Assets to be sold.

11.6 Valid Receipts

A Receiver may give valid receipt for all monies and execute all assurances and things that may be proper or desirable for realising any of the Secured Assets.

11.7 Make Settlements

A Receiver may make any arrangement, settlement or compromise between the Chargor and any other person that he may think expedient.

11.8 Bring Proceedings

A Receiver may bring, prosecute, enforce, defend and abandon all actions, suits and proceedings in relation to any of the Secured Assets as he thinks fit.

11.9 Insure

A Receiver may, if he thinks fit, but without prejudice to the indemnity in clause 14, effect with any insurer any policy of insurance either in lieu or satisfaction of, or in addition to, the insurance required to be maintained by the Chargor under this deed.

11.10 Redeem Prior Security

A Receiver may redeem any prior Security and settle and pass the accounts to which the Security relates. Any accounts so settled and passed shall be, in the absence of any manifest error, conclusive and binding on the Chargor, and the monies so paid shall be deemed to be an expense properly incurred by the Receiver.

11.11 Delegation

A Receiver may delegate his powers in accordance with this deed.

11.12 Absolute Beneficial Owner

A Receiver may, in relation to any of the Secured Assets, exercise all powers, authorisations and rights he would be capable of exercising, and do all those acts and things, as an absolute

beneficial owner could exercise or do in the ownership and management of the Secured Assets or any part of the Secured Assets.

11.13 Incidental Powers

A Receiver may do any other acts and things:

- (a) that he may consider desirable or necessary for realising any of the Secured Assets;
- (b) that he may consider incidental or conducive to any of the rights or powers conferred on a Receiver under or by virtue of this deed or law; or
- (c) that he lawfully may or can do as agent for the Chargor.

12. DELEGATION

12.1 Delegation

The Security Trustee (acting on the instructions of the Lender Majority) or any Receiver may delegate (either generally or specifically) by power of attorney or in any other manner to any person any right, power, authority or discretion conferred on it by this deed.

12.2 Terms

The Security Trustee (acting on the instructions of the Lender Majority) and each Receiver may make a delegation on the terms and conditions (including the power to sub-delegate) that it thinks fit.

12.3 Liability

Neither the Security Trustee nor any Receiver shall be in any way liable or responsible to the Chargor for any loss or liability arising from any act, default, omission or misconduct on the part of any Delegate, except in cases of fraud, willful default or negligence by such Delegate.

13. APPLICATION OF PROCEEDS

13.1 Order of Application of Proceeds

All monies received by the Security Trustee, a Receiver or a Delegate pursuant to this deed, after the Security constituted by this deed has become enforceable, shall be applied in the following order of priority:

- (a) in or towards payment of or provision for all costs, charges and expenses incurred by or on behalf of such Security Trustee (and any Receiver, Delegate, attorney or agent appointed by it) under or in connection with this deed, and of all remuneration due to any Receiver under or in connection with this deed;
- (b) in or towards payment of or provision for the Secured Liabilities in any order and manner that such Security Trustee (acting on the instructions of the Lender Majority) determines; and
- (c) in payment of the surplus (if any) to the Chargor or other person entitled to it.

14. COSTS

14.1 Costs

The Chargor shall, on demand, pay to, or reimburse, the Security Trustee and any Receiver, on a full indemnity basis, all reasonable costs, charges, expenses, taxes and liabilities incurred by the Security Trustee, any Receiver or any Delegate in connection with:

- (a) taking, holding, protecting, perfecting, preserving or enforcing (or attempting to do so) any of the Security Trustee's, a Receiver's or a Delegate's rights under this deed; or
- (b) taking proceedings for, or recovering, any of the Secured Liabilities,

together with interest, which shall accrue and be payable (without the need for any demand for payment being made) from the date on which the relevant cost or expense arose until full discharge of that cost or expense (whether before or after judgment, liquidation, winding up or administration of the Chargor) at the rate and in the manner specified in the Instrument.

15. FURTHER ASSURANCE

15.1 Further Assurance

The Chargor shall, at its own expense, take whatever action the Security Trustee (acting on the instructions of the Lender Majority) or any Receiver may reasonably require for:

- 15.1.1 creating, perfecting or protecting the Security intended to be created by this deed;
- 15.1.2 facilitating the realisation of any of its Secured Assets; or
- 15.1.3 facilitating the exercise of any right, power, authority or discretion exercisable by the Security Trustee (acting on the instructions of the Lender Majority) or any Receiver in respect of any of its Secured Assets,

including, without limitation (if the Security Trustee (acting on the instructions of the Lender Majority) or the Receiver think it expedient) the execution of any transfer, conveyance, assignment or assurance of all or any of the assets forming part of (or intended to form part of) the Secured Assets (whether to the Security Trustee or to its nominee) and the giving of any notice, order or direction and the making of any registration.

16. RELEASE

On the expiry of the Security Period, the Security Trustee (acting on the instructions of the Lender Majority) shall, promptly, take whatever action is necessary to:

- 16.1.1 release the Secured Assets from the Security constituted by this deed; and
- 16.1.2 reassign the Secured Assets to the Chargor.

17. ASSIGNMENT AND TRANSFER

17.1 Assignment By Security Trustee

- (a) The Security Trustee may only assign its rights or transfer any of its obligations under this deed, or enter into a transaction that would result in these rights or obligations passing to another person, to a person to whom it assigns its rights or transfers its obligations in compliance with the assignment and transfer provisions in the Instrument or the Security Trust Deed.
- (b) The Security Trustee may disclose to any actual or proposed assignee or transferee any information in its possession that relates to the Chargor, the Secured Assets and this deed that the Security Trustee considers reasonably appropriate.

17.2 Assignment By Chargor

The Chargor may not assign any of its rights, or transfer any of its rights or obligations, under this deed without the prior written consent of the Security Trustee (acting on the instructions of the Lender Majority).

18. AMENDMENTS, WAIVERS AND CONSENTS

18.1 Amendments

No amendment of this deed shall be effective unless it is in writing and signed by, or on behalf of, each party (or its authorised representative).

18.2 Waivers and Consents

- (a) A waiver of any right or remedy under this deed or by law, or any consent given under this deed, is only effective if given in writing by the waiving or consenting party and shall not be deemed a waiver of any other breach or default. It only applies in the circumstances for which it is given and shall not prevent the party giving it from subsequently relying on the relevant provision.
- (b) A failure or delay by a party to exercise any right or remedy provided under this deed or by law shall not constitute a waiver of that or any other right or remedy, prevent or restrict any further exercise of that or any other right or remedy or constitute an election to affirm this deed. No single or partial exercise of any right or remedy provided under this deed or by law shall prevent or restrict the further exercise of that or any other right or remedy. No election to affirm this deed by the Security Trustee (acting on the instructions of the Lender Majority) shall be effective unless it is in writing.

18.3 Rights and Remedies

The rights and remedies provided under this deed are cumulative and are in addition to, and not exclusive of, any rights and remedies provided by law.

19. SEVERANCE

19.1 Severance

If any provision (or part of a provision) of this deed is or becomes invalid, illegal or unenforceable, it shall be deemed modified to the minimum extent necessary to make it valid, legal and enforceable. If such modification is not possible, the relevant provision (or part of a provision) shall be deemed deleted. Any modification to or deletion of a provision (or part of a provision) under this clause shall not affect the legality, validity and enforceability of the rest of this deed.

20. COUNTERPARTS

20.1 Counterparts

- 20.1.1 This deed may be executed in any number of counterparts, each of which when executed and delivered shall constitute a duplicate original, but all the counterparts shall together constitute one deed.
- 20.1.2 Transmission of an executed counterpart of this deed (but for the avoidance of doubt not just a signature page) by fax or e-mail (in PDF, JPEG or other agreed format) shall take effect as delivery of an executed counterpart of this deed. If either method of delivery is adopted, without prejudice to the validity of the deed thus made, each party shall provide the others with the original of such counterpart as soon as reasonably possible thereafter.

21. THIRD PARTY RIGHTS

21.1 Third Party Rights

- 21.1.1 Except as expressly provided elsewhere in this deed, a person who is not a party to this deed shall not have any rights under the Contracts (Rights of Third Parties) Act 1999 to enforce, or enjoy the benefit of, any term of this deed. This does not affect any right or remedy of a third party which exists, or is available, apart from that Act.
- 21.1.2 The rights of the parties to rescind or agree any amendment or waiver under this deed are not subject to the consent of any other person.

22. FURTHER PROVISIONS

22.1 Independent Security

This deed shall be in addition to, and independent of, any other security or guarantee that the Security Trustee may hold for any of the Secured Liabilities at any time. No prior security held by the Security Trustee over the whole or any part of the Secured Assets shall merge in the Security created by this deed.

22.2 Continuing Security

This deed shall remain in full force and effect as a continuing security for the Secured Liabilities, despite any settlement of account, or intermediate payment, or other matter or thing, unless and until the Security Trustee discharges this deed in writing.

22.3 Certificates

A certificate or determination by the Security Trustee as to any amount for the time being due to it from the Chargor under this deed shall be, in the absence of any manifest error, conclusive evidence of the amount due.

23. NOTICES

23.1 Delivery

Any notice or other communication required to be given to a party under or in connection with this deed shall be:

- (a) in writing;

(b) delivered by hand, by pre-paid first-class post or other next working day delivery service or sent by fax; and

(c) sent to:

(i) the Chargor at: Paul Foulger, CFO, Novabiotics Limited, Cruickshank Building Craibstone, Bucksburn, Aberdeen, Scotland AB21 9TR

E-mail: paulf@novabiotics.co.uk

Attention: Paul Foulger, CFO

(ii) the Security Trustee at: Barwell plc, Sterling House, 20 Renfield Street, Glasgow G2 5AP

E-mail: AMackie@barwell-group.com

Attention: Alec Mackie

or to any other address or fax number as is notified in writing by one party to the other from time to time.

23.2 Receipt By Chargor and Security Trustee

Any notice or other communication given by either party to the other pursuant to this deed shall be deemed to have been received:

- (a) if delivered by hand, at the time it is left at the relevant address;
- (b) if posted by pre-paid first-class post or other next working day delivery service, on the second Business Day after posting;
- (c) if sent by fax, when received in legible form; and
- (d) if sent by e-mail and no delivery failure is reported to or by the sender's e-mail server, be deemed to have been given and received on the date such e-mail was sent.

A notice or other communication given as described in clause 23.2(a), clause 23.2(c), or clause 23.2 (d) on a day that is not a Business Day, or after normal business hours, in the place it is received, shall be deemed to have been received on the next Business Day.

23.3 Service of Proceedings

This clause 23 does not apply to the service of any proceedings or other documents in any legal action or, where applicable, any arbitration or other method of dispute resolution.

24. GOVERNING LAW AND JURISDICTION

24.1 Governing Law

This deed and any dispute or claim arising out of or in connection with it or its subject matter or formation (including non-contractual disputes or claims) shall be governed by and construed in accordance with the law of England and Wales.

24.2 Jurisdiction

Each party irrevocably agrees that, subject as provided below, the courts of England and Wales shall have exclusive jurisdiction over any dispute or claim arising out of or in connection with this deed or its subject matter or formation (including non-contractual disputes or claims).

IN WITNESS THIS DEED has been executed by the parties and is intended to be and is delivered on the date appearing on its first page.

SCHEDULE 1 - PATENT PORTFOLIO AS AT 21 JUNE 2018

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
0129P/AU	Australia	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	2006327973	26 Jul 2012	2006327973
0129P/AU1	Australia	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	2012203804	29 Jan 2015	2012203804
0129P/BR	Brazil	Cyclic peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	PI 0619641-1	09 Jan 2018	PI 0619641-1
0129P/CA	Canada	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	2655448	06 Sep 2016	2655448
0129P/CN	China	Cyclic peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	200680053281.0	07 Aug 2013	ZL200680053281.0
0129P/CN1	China	Cyclic peptides	Pending	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	2013102995185		
0129P/EP	EPO	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863
0129P/EP1	EPO	Cyclic Peptides	Pending	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	EP11001654.0		
0129P/EP2	EPO	Cyclic Peptides	Abandoned	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	EP11001658.1		
0129P/EP3	EPO	Cyclic Peptides	Abandoned	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	EP11001659.9		
0129P/EPA T	Austria	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863
0129P/EPBE	Belgium	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863
0129P/EPBG	Bulgaria	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863
0129P/EPCH	Switzerland	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863
0129P/EPCY	Cyprus	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863
0129P/EPCZ	Czechia	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863
0129P/EPDE	Germany	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
0129P/EPDK	Denmark	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863
0129P/EPEE	Estonia	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863
0129P/EPES	Spain	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863
0129P/EPFI	Finland	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863
0129P/EPFR	France	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863
0129P/EPGB	UK	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863
0129P/EPGR	Greece	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863
0129P/EPHU	Hungary	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863
0129P/EPIE	Ireland	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863
0129P/EPIS	Iceland	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863
0129P/EPIT	Italy	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863
0129P/EPLT	Lithuania	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863
0129P/EPLU	Luxembourg	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863
0129P/EPLV	Latvia	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863
0129P/EPMC	Monaco	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863
0129P/EPNL	Netherlands	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863
0129P/EPPL	Poland	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863
0129P/EPPT	Portugal	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
0129P/EPRO	Romania	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863
0129P/EPSE	Sweden	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863
0129P/EPSE	Slovenia	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863
0129P/EPSE	Slovakia	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863
0129P/EPSE	Turkey	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	06842187.4	12 Dec 2012	EP1976863
0129P/GB	UK	Cyclic Peptides	Abandoned		22 Dec 2005	0526120.1			
0129P/HK	Hong Kong	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	08112867.7	31 May 2013	HK1121462
0129P/HK1	Hong Kong	Cyclic Peptides	Pending	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	11108165.9		
0129P/IL	Israel	Cyclic peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	192373	25 Dec 2015	192373
0129P/IL1	Israel	Cyclic peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	240686	01 Nov 2017	240686
0129P/IN	India	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	2962/KOLNP/2008	27 Jul 2017	285712
0129P/JP	Japan	Cyclic peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	2008-546630	13 Jun 2014	5559477
0129P/JP1	Japan	Cyclic peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	2012-252220	02 Dec 2016	6050096
0129P/JP2	Japan	Cyclic peptides	Granted	21 Dec 2005	21 Dec 2006	PCT/GB2006/004890	2014-090998	01 Sep 2017	6199797
0129P/KR	Republic of Korea	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	10-2008-7017946	24 Jun 2014	10-1413746
0129P/MX	Mexico	Cyclic peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	MX/a/2008/008291	15 Dec 2011	293888
0129P/NO	Norway	Cyclic Peptides	Pending	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	20083245		

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
0129P/NZ	New Zealand	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	569946	02 Apr 2012	569946
0129P/RU	Russian Federation	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	2008129866	10 Oct 2012	2463308
0129P/SG	Singapore	Cyclic peptides	Abandoned	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	200804740-9		
0129P/SG1	Singapore	Cyclic peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	201009320-1	18 Jul 2014	167876
0129P/SG2	Singapore	Cyclic peptides	Pending	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	10201403126R		
0129P/UA	Ukraine	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	a 2008 09609	12 Mar 2012	97633
0129P/US	USA	Cyclic peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	12/158,945	04 Dec 2012	8324154
0129P/US1	USA	Cyclic peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	13/592,246	22 Jul 2014	8785375
0129P/US2	USA	Cyclic peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	14/311093	10 Nov 2015	9181303
0129P/US3	USA	Cyclic peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	14/936,474	13 Dec 2016	9518093
0129P/USpriority	USA	Cyclic Peptides	Abandoned		24 Feb 2006	60/776,505			
0129P/WO	WIPO	Cyclic peptides	Ceased/Matured PCT	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890			
0129P/ZA	South Africa	Cyclic Peptides	Granted	22 Dec 2005	21 Dec 2006	PCT/GB2006/004890	2008/06329	27 Jan 2010	2008/06329
0131P/AT	Austria	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720
0131P/AU	Australia	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	2005273638	12 Jan 2012	2005273638
0131P/AU1	Australia	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	2011235933	20 Sep 2012	2011235933
0131P/AU2	Australia	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	2012216615	23 Jul 2015	2012216615

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
0131P/BE	Belgium	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720
0131P/BG	Bulgaria	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720
0131P/BR	Brazil	Peptides	Pending	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	PI 0514420-5		
0131P/CA	Canada	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	2,575,058	12 Sep 2017	2,575,058
0131P/CA1	Canada	Peptides	Pending	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	2974538		
0131P/CH	Switzerland	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720
0131P/CN	China	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	200580028121.6	05 Jun 2013	ZL 200580028121.6
0131P/CN1	China	Peptides	Abandoned	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	201310161891.4		
0131P/CN2	China	Peptides	Abandoned	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	201310161743.2		
0131P/CY	Cyprus	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720
0131P/CZ	Czechia	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720
0131P/DE	Germany	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720
0131P/DK	Denmark	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720
0131P/EE	Estonia	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720
0131P/EP	EPO	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720
0131P/EP1	EPO	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	08001112.5	02 Nov 2016	1927597
0131P/EP1BE	Belgium	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	08001112.5	02 Nov 2016	1927597
0131P/EP1DE	Germany	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	08001112.5	02 Nov 2016	1927597

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
0131P/EP/DK	Denmark	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	08001112.5	02 Nov 2016	1927597
0131P/EP/ES	Spain	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	08001112.5	02 Nov 2016	1927597
0131P/EP/FR	France	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	08001112.5	02 Nov 2016	1927597
0131P/EP/GB	UK	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	08001112.5	02 Nov 2016	1927597
0131P/EP/IE	Ireland	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	08001112.5	02 Nov 2016	1927597
0131P/EP/IT	Italy	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	08001112.5	02 Nov 2016	1927597
0131P/EP/NL	Netherlands	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	08001112.5	02 Nov 2016	1927597
0131P/EP/PT	Portugal	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	08001112.5	02 Nov 2016	1927597
0131P/EP/SE	Sweden	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	08001112.5	02 Nov 2016	1927597
0131P/EP2	EPO	Peptides	Abandoned	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	09005438.8		
0131P/EP3	EPO	Peptides	Pending	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	16176481.6		
0131P/EP4	EPO	Peptides	Pending	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	16179810.3		
0131P/ES	Spain	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720
0131P/FI	Finland	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720
0131P/FR	France	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720
0131P/GB	UK	Peptides	Abandoned		18 Aug 2004	0418414.9			
0131P/GB1	UK	Peptides	Abandoned	18 Aug 2004	18 Aug 2005	0703060.4			
0131P/GB2	UK	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
0131P/GR	Greece	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720
0131P/HK	Hong Kong	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	07110561.1	18 Feb 2011	HK1105982
0131P/HK1	Hong Kong	Peptides	Abandoned	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	14100386.6		
0131P/HK2	Hong Kong	Peptides	Abandoned	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	10102229.7		
0131P/HK3	Hong Kong	Peptides	Pending	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	17103760.3		
0131P/HK4	Hong Kong	Peptides	Pending	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	17105515.6		
0131P/HU	Hungary	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720
0131P/IE	Ireland	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720
0131P/IL	Israel	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	180727	01 Oct 2015	180727
0131P/IL1	Israel	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	213319	01 Nov 2017	213319
0131P/IN	India	Peptides	Abandoned	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	0870/KOLNP/2007		
0131P/IN1	India	Peptides	Abandoned	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	0307/KOL/2010		
0131P/IS	Iceland	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720
0131P/IT	Italy	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720
0131P/JP	Japan	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	2007-526571	22 Jun 2012	5020078
0131P/KR	Republic of Korea	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	10-2007-7003571	13 Feb 2013	10-1234780
0131P/LT	Lithuania	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
0131P/LU	Luxembourg	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720
0131P/LV	Latvia	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720
0131P/MC	Monaco	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720
0131P/MX	Mexico	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	MX/A/2007/002057	20 Sep 2010	279070
0131P/NL	Netherlands	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720
0131P/NO	Norway	Peptides	Allowed/Accepted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	20071369		
0131P/NZ	New Zealand	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	553494	06 Nov 2010	553494
0131P/NZ1	New Zealand	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	584340	08 Jan 2011	584340
0131P/PL	Poland	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720
0131P/PT	Portugal	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720
0131P/RO	Romania	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720
0131P/RU	Russian Federation	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	2007109518	10 Aug 2010	2396273
0131P/SE	Sweden	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720
0131P/SG	Singapore	Peptides	Abandoned	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	200700443-5		
0131P/SG1	Singapore	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	200905379-4	15 Mar 2013	155211
0131P/SG2	Singapore	Peptides	Abandoned	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	201300735-9		
0131P/SG3	Singapore	Peptides	Pending	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	10201606278U		

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
0131P/SI	Slovenia	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720
0131P/SK	Slovakia	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720
0131P/TR	Turkey	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	05778505.7	01 Sep 2010	EP1778720
0131P/UA	Ukraine	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	UA a 200701921	25 Nov 2011	96564
0131P/US	USA	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	11/573,770	07 Dec 2010	7,847,059
0131P/US1	USA	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	12/893,663	03 Jan 2012	8,088,888
0131P/US2	USA	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	13/170,975	08 Jan 2013	8350003
0131P/US3	USA	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	13/308,479	25 Jun 2013	8,470,769
0131P/USpriority	USA	Peptides	Abandoned		14 Mar 2005	11/079,795			
0131P/WO	WIPO	Peptides	Ceased/Matured PCT	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245			
0131P/ZA	South Africa	Peptides	Granted	18 Aug 2004	18 Aug 2005	PCT/GB2005/003245	2007/01394	29 Oct 2008	2007/01394
0132P/AU	Australia	Glycosidic Coumarin Compounds and their use	Abandoned	06 Jun 2006	05 Jun 2007	PCT/GB2007/002062	2007255176	04 Mar 2013	2007255176
0132P/CA	Canada	Glycosidic Coumarin Compounds and their use	Abandoned	06 Jun 2006	05 Jun 2007	PCT/GB2007/002062	2654370		
0132P/CN	China	Glycosidic Coumarin Compounds and	Abandoned	06 Jun 2006	05 Jun 2007	PCT/GB2007/002062	200780029384.8		

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
		their use							
0132P/EP	EPO	Glycosidic Coumarin Compounds and their use	Abandoned	06 Jun 2006	05 Jun 2007	PCT/GB2007/002062	07733077.7		
0132P/GB	UK	Compounds and their use	Abandoned		06 Jun 2006	0611115.7			
0132P/IN	India	Glycosidic Coumarin Compounds and their use	Abandoned	06 Jun 2006	05 Jun 2007	PCT/GB2007/002062	0032/KOLNP/2009		
0132P/JP	Japan	Glycosidic Coumarin Compounds and their use	Abandoned	06 Jun 2006	05 Jun 2007	PCT/GB2007/002062	2009-513756	24 May 2013	5276583
0132P/NZ	New Zealand	Glycosidic Coumarin Compounds and their use	Abandoned	06 Jun 2006	05 Jun 2007	PCT/GB2007/002062	573434	07 Feb 2012	573434
0132P/US	USA	Compounds and their use	Abandoned	06 Jun 2006	05 Jun 2007	PCT/GB2007/002062	12/303,958		
0132P/USpriority	USA	Compounds and their use	Abandoned		02 Aug 2006	60/821228			
0132P/WO	WIPO	Glycosidic Coumarin Compounds and their use	Ceased/Matured PCT	06 Jun 2006	05 Jun 2007	PCT/GB2007/002062			
0159P/AU	Australia	Antifungal Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	2008211789	27 Feb 2014	2008211789

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
0159P/CA	Canada	Antifungal Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	2706744	05 Dec 2017	2706744
0159P/CN	China	Antifungal Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	200880009167.7	03 Apr 2018	ZL200880009167.7
0159P/EP	EPO	Antifungal Peptides	Abandoned	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	08701955.0		
0159P/EP1	EPO	Antifungal Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1A.T	Austria	Antifungal Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1BE	Belgium	Antifungal Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1BG	Bulgaria	Antifungal Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1CH	Switzerland	Antifungal Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1CY	Cyprus	Antifungal Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1CZ	Czechia	Antifungal Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1DE	Germany	Antifungal Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1DK	Denmark	Antifungal Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1EE	Estonia	Antifungal Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1ES	Spain	Antifungal Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1FI	Finland	Antifungal Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1FR	France	Antifungal Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1GB	UK	Antifungal Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1GR	Greece	Antifungal Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
0159P/EP1HR	Croatia	AntifungalPeptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1HU	Hungary	AntifungalPeptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1IE	Ireland	AntifungalPeptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1IS	Iceland	AntifungalPeptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1IT	Italy	AntifungalPeptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1LI	Liechtenstein	AntifungalPeptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1LT	Lithuania	AntifungalPeptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1LU	Luxembourg	AntifungalPeptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1LV	Latvia	AntifungalPeptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1MC	Monaco	AntifungalPeptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1MT	Malta	AntifungalPeptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1NL	Netherlands	AntifungalPeptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1NO	Norway	AntifungalPeptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1PL	Poland	AntifungalPeptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1PT	Portugal	AntifungalPeptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1RO	Romania	AntifungalPeptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1SE	Sweden	AntifungalPeptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP1SI	Slovenia	AntifungalPeptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
0159P/EP/ISK	Slovakia	Antifungal Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/EP/TR	Turkey	Antifungal Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10009304.6	15 Jan 2014	EP2251348
0159P/GB	UK	Antifungal Peptides	Abandoned		02 Feb 2007	0702020.9			
0159P/HK	Hong Kong	Antifungal Peptides	Abandoned	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10106053.9		
0159P/HK1	Hong Kong	Antifungal Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	10112002.9	02 May 2014	HK1145506
0159P/IN	India	Antifungal Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	3036/KOLNP/2009	19 Jun 2017	283860
0159P/JP	Japan	Antifungal Peptides	Abandoned	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	2009-547750		
0159P/JP1	Japan	Antifungal Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	JP2013-141102	12 Feb 2016	5882260
0159P/NZ	New Zealand	Antifungal Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	578970	06 Aug 2012	578970
0159P/US	USA	Antifungal Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283	12/525,523	27 Oct 2015	9,169,290
0159P/USpriority	USA	Antifungal Peptides	Abandoned		02 Feb 2007	60/899,283			
0159P/WO	WIPO	Antifungal Peptides	Ceased/Matured PCT	02 Feb 2007	28 Jan 2008	PCT/GB2008/000283			
0174P/AU	Australia	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	2008211787	30 Jan 2014	2008211787
0174P/CA	Canada	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	2706621	05 Dec 2017	2706621
0174P/CN	China	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	200880009199.7	06 Nov 2013	ZL200880009199.7
0174P/EP	EPO	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
0174P/EPAT	Austria	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPBE	Belgium	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPBG	Bulgaria	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPCH	Switzerland	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPCY	Cyprus	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPCZ	Czechia	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPDE	Germany	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPDK	Denmark	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPEE	Estonia	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPES	Spain	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPFI	Finland	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPFR	France	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPGB	UK	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
0174P/EPGR	Greece	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPHR	Croatia	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPHU	Hungary	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPHE	Ireland	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPIS	Iceland	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPIT	Italy	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPLI	Liechtenstein	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPLT	Lithuania	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPLU	Luxembourg	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPLV	Latvia	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPMC	Monaco	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPMT	Malta	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPNL	Netherlands	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
0174P/EPNO	Norway	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPPL	Poland	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPPT	Portugal	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPRO	Romania	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPSE	Sweden	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPSE	Slovenia	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPSE	Slovakia	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/EPTR	Turkey	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	08701953.5	28 Jan 2015	EP2125871
0174P/GB	UK	Antibacterial Peptides	Abandoned		02 Feb 2007	0702021.7			
0174P/HK	Hong Kong	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	HK10105372.5	04 Sep 2015	HK1139421
0174P/JP	Japan	Antibacterial Peptides	Abandoned	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	2009-547748		
0174P/JP1	Japan	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	JP2013-136967	05 Jun 2015	5756495
0174P/NZ	New Zealand	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	578951	09 Jul 2012	578951

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
0174P/US	USA	Antibacterial Peptides	Granted	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281	12/525,519	21 Jun 2016	9371363
0174P/USpriority	USA	Antibacterial Peptides	Abandoned		02 Feb 2007	60/899,149			
0174P/WO	WIPO	Antibacterial Peptides	Ceased/Maintained PCT	02 Feb 2007	28 Jan 2008	PCT/GB2008/000281			
0175P/AU	Australia	Treatment of mixed pathogen infections	Abandoned	02 Feb 2007	28 Jan 2008	PCT/GB2008/000282	2008211788		
0175P/CA	Canada	Treatment of mixed pathogen infections	Abandoned	02 Feb 2007	28 Jan 2008	PCT/GB2008/000282	2706738		
0175P/CN	China	Treatment of mixed pathogen infections	Abandoned	02 Feb 2007	28 Jan 2008	PCT/GB2008/000282	200880009157.3		
0175P/EP	EPO	Treatment of mixed pathogen infections	Abandoned	02 Feb 2007	28 Jan 2008	PCT/GB2008/000282	08701954.3		
0175P/GB	UK	Treatment of mixed pathogen infections	Abandoned		02 Feb 2007	0702022.5			
0175P/HK	Hong Kong	Treatment of mixed pathogen infections	Abandoned	02 Feb 2007	28 Jan 2008	PCT/GB2008/000282	HK10105373.4		
0175P/JP	Japan	Treatment of mixed pathogen infections	Abandoned	02 Feb 2007	28 Jan 2008	PCT/GB2008/000282	2009-547749		
0175P/NZ	New Zealand	Treatment of mixed pathogen infections	Abandoned	02 Feb 2007	28 Jan 2008	PCT/GB2008/000282	578912		
0175P/US	USA	Treatment of mixed pathogen infections	Abandoned	02 Feb 2007	28 Jan 2008	PCT/GB2008/000282	12/525,518		
0175P/USpriority	USA	Treatment of mixed pathogen infections	Abandoned		02 Feb 2007	60/899,167			

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
0175P/WO	WIPO	Treatment of mixed pathogen infections	Ceased/Matured PCT	02 Feb 2007	28 Jan 2008	PCT/GB2008/000282			
0776P/AU	Australia	Biofilms	Granted	31 Mar 2009	31 Mar 2010	PCT/GB2010/000631	2010231136	24 Nov 2016	2010231136
0776P/AU1	Australia	Biofilms	Granted	31 Mar 2009	31 Mar 2010	PCT/GB2010/000631	2016210742	23 Nov 2017	2016210742
0776P/BR	Brazil	Biofilms	Pending	31 Mar 2009	31 Mar 2010	PCT/GB2010/000631	P11012219-2		
0776P/CA	Canada	Biofilms	Granted	31 Mar 2009	31 Mar 2010	PCT/GB2010/000631	2,755,878	24 Apr 2018	2,755,878
0776P/CN	China	Biofilms	Granted	31 Mar 2009	31 Mar 2010	PCT/GB2010/000631	2010800148969	25 Nov 2015	ZL2010800148969
0776P/CN1	China	Biofilms	Pending	31 Mar 2009	31 Mar 2010	PCT/GB2010/000631	2014104195437		
0776P/EP	EPO	Biofilms	Allowed/Acc epted	31 Mar 2009	31 Mar 2010	PCT/GB2010/000631	EP10715573.1		
0776P/GB	UK	Inhibition of biofilm microorganisms	Abandoned		31 Mar 2009	0905451.1			
0776P/HK	Hong Kong	Biofilms	Pending	31 Mar 2009	31 Mar 2010	PCT/GB2010/000631	12101621.1		
0776P/IL	Israel	Biofilms	Pending	31 Mar 2009	31 Mar 2010	PCT/GB2010/000631	IL 215369		
0776P/IN	India	Biofilms	Pending	31 Mar 2009	31 Mar 2010	PCT/GB2010/000631	1958/MUMNP/2011		
0776P/JP	Japan	Biofilms	Granted	31 Mar 2009	31 Mar 2010	PCT/GB2010/000631	2012-502770	10 Apr 2015	5727994
0776P/KR	Republic of Korea	Biofilms	Granted	31 Mar 2009	31 Mar 2010	PCT/GB2010/000631	10-2011-7024561	23 Apr 2018	10-1852784
0776P/MX	Mexico	Biofilms	Allowed/Acc epted	31 Mar 2009	31 Mar 2010	PCT/GB2010/000631	MX/A/2011/010258		
0776P/NZ	New Zealand	Biofilms	Granted	31 Mar 2009	31 Mar 2010	PCT/GB2010/000631	595037	30 Oct 2013	595037

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
0776P/RU	Russian Federation	Biofilms	Granted	31 Mar 2009	31 Mar 2010	PCT/GB2010/000631	2011143399	20 Apr 2015	2548786
0776P/SG	Singapore	Biofilms	Abandoned	31 Mar 2009	31 Mar 2010	PCT/GB2010/000631	201106441.7		
0776P/SGI	Singapore	Biofilms	Pending	31 Mar 2009	31 Mar 2010	PCT/GB2010/000631	10201400926V		
0776P/UA	Ukraine	Biofilms	Granted	31 Mar 2009	31 Mar 2010	PCT/GB2010/000631	a201110832	10 Oct 2014	106743
0776P/US	USA	Biofilms	Granted	31 Mar 2009	31 Mar 2010	PCT/GB2010/000631	13/260,547	17 May 2016	9339525
0776P/USI	USA	Biofilms	Pending	31 Mar 2009	31 Mar 2010	PCT/GB2010/000631	15/082,976		
0776P/USPriority	USA	Inhibition of biofilm microorganisms	Abandoned		31 Mar 2009	61/165,396			
0776P/WO	WIPO	Biofilms	Ceased/Matured PCT	31 Mar 2009	31 Mar 2010	PCT/GB2010/000631			
0776P/ZA	South Africa	Biofilms	Granted	31 Mar 2009	31 Mar 2010	PCT/GB2010/000631	2011/07140	27 Jun 2012	2011/07140
10400P/AE	United Arab Emirates	Treatment of Malassezia infections	Abandoned	14 Mar 2012	14 Mar 2013	PCT/GB2013/000112	956/2014		
10400P/AU	Australia	Treatment of Malassezia infections	Abandoned	14 Mar 2012	14 Mar 2013	PCT/GB2013/000112	2013234122		
10400P/BR	Brazil	Treatment of Malassezia infections	Abandoned	14 Mar 2012	14 Mar 2013	PCT/GB2013/000112	BR 11 2014 022680 6		
10400P/CA	Canada	Treatment of Malassezia infections	Abandoned	14 Mar 2012	14 Mar 2013	PCT/GB2013/000112	2866837		

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
10400P/CL	Chile	Treatment of Malassezia infections	Abandoned	14 Mar 2012	14 Mar 2013	PCT/GB2013/000112	2014-2397		
10400P/CN	China	Treatment of Malassezia infections	Abandoned	14 Mar 2012	14 Mar 2013	PCT/GB2013/000112	2013800144105		
10400P/EP	EPO	Treatment of Malassezia infections	Abandoned	14 Mar 2012	14 Mar 2013	PCT/GB2013/000112	13718609.4		
10400P/GB	UK	Treatment of Malassezia infections	Abandoned		14 Mar 2012	1204457.4			
10400P/HK	Hong Kong	Treatment of Malassezia infections	Abandoned	14 Mar 2012	14 Mar 2013	PCT/GB2013/000112	15101528.2		
10400P/IL	Israel	Treatment of Malassezia infections	Abandoned	14 Mar 2012	14 Mar 2013	PCT/GB2013/000112	IL 234646		
10400P/IN	India	Treatment of Malassezia infections	Abandoned	14 Mar 2012	14 Mar 2013	PCT/GB2013/000112	2096/KOLNP/2014		
10400P/JP	Japan	Treatment of Malassezia infections	Abandoned	14 Mar 2012	14 Mar 2013	PCT/GB2013/000112	JP 2014-561504		
10400P/KR	Republic of Korea	Treatment of Malassezia infections	Abandoned	14 Mar 2012	14 Mar 2013	PCT/GB2013/000112	10-2014-7028818		
10400P/MX	Mexico	Treatment of Malassezia	Abandoned	14 Mar 2012	14 Mar 2013	PCT/GB2013/000112	MX/A/2014/010996		

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
		infections							
10400P/NZ	New Zealand	Treatment of Malassezia infections	Abandoned	14 Mar 2012	14 Mar 2013	PCT/GB2013/000112	700467	29 Nov 2016	700467
10400P/RU	Russian Federation	Treatment of Malassezia infections	Abandoned	14 Mar 2012	14 Mar 2013	PCT/GB2013/000112	2014139857		
10400P/SG	Singapore	Treatment of Malassezia infections	Abandoned	14 Mar 2012	14 Mar 2013	PCT/GB2013/000112	11201405539Q		
10400P/UA	Ukraine	Treatment of Malassezia infections	Abandoned	14 Mar 2012	14 Mar 2013	PCT/GB2013/000112	A 2014 10697		
10400P/US	USA	Treatment of Malassezia infections	Abandoned	14 Mar 2012	14 Mar 2013	PCT/GB2013/000112	14/004,344		
10400P/USpriority	USA	Treatment of Malassezia infections	Abandoned		05 Apr 2012	61/620,833			
10400P/WO	WIPO	Treatment of Malassezia infections	Ceased/Matured PCT	14 Mar 2012	14 Mar 2013	PCT/GB2013/000112			
10400P/ZA	South Africa	Treatment of Malassezia infections	Abandoned	14 Mar 2012	14 Mar 2013	PCT/GB2013/000112	2014/07276	24 Jun 2015	2014/07276
11838P/EP	EPO	Modified polyarginine peptides	Withdrawn	02 Apr 2014	02 Apr 2015	PCT/GB2015/051039	15715388.3		

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
11838P/GB	UK	Modified polyarginine peptides	Abandoned		02 Apr 2014	1405891.1			
11838P/US	USA	Modified polyarginine peptides	Abandoned	02 Apr 2014	02 Apr 2015	PCT/GB2015/051039	15/301,472		
11838P/USpriority	USA	Modified polyarginine peptides	Abandoned		02 Apr 2014	61/974,087			
11838P/WO	WIPO	Modified polyarginine peptides	Ceased/Matured PCT	02 Apr 2014	02 Apr 2015	PCT/GB2015/051039			
13692P/AU	Australia	Cysteamine for treating yeast and mould infections	Allowed/Accepted	22 Sep 2014	21 Sep 2015	PCT/GB2015/052714	2015323566		
13692P/BR	Brazil	Cysteamine for treating yeast and mould infections	Pending	22 Sep 2014	21 Sep 2015	PCT/GB2015/052714	BR 11 2017 005272 5		
13692P/CA	Canada	Cysteamine for treating yeast and mould infections	Pending	22 Sep 2014	21 Sep 2015	PCT/GB2015/052714	2,959,003		
13692P/CN	China	Cysteamine for treating yeast and mould infections	Pending	22 Sep 2014	21 Sep 2015	PCT/GB2015/052714	2015800510647		
13692P/EP	EPO	Cysteamine for treating yeast and mould infections	Pending	22 Sep 2014	21 Sep 2015	PCT/GB2015/052714	15770619.3		
13692P/GB	UK	Cysteamine for treating yeast and	Abandoned		22 Sep 2014	1416727.4			

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
		mould infections							
13692P/HK	Hong Kong	Cysteamine for treating yeast and mould infections	Pending	22 Sep 2014	21 Sep 2015	PCT/GB2015/052714	17109968.0		
13692P/IL	Israel	Cysteamine for treating yeast and mould infections	Pending	22 Sep 2014	21 Sep 2015	PCT/GB2015/052714	251040		
13692P/IN	India	Cysteamine for treating yeast and mould infections	Pending	22 Sep 2014	21 Sep 2015	PCT/GB2015/052714	201727013333		
13692P/JP	Japan	Cysteamine for treating yeast and mould infections	Pending	22 Sep 2014	21 Sep 2015	PCT/GB2015/052714	JP2017-515704		
13692P/KR	Republic of Korea	Cysteamine for treating yeast and mould infections	Pending	22 Sep 2014	21 Sep 2015	PCT/GB2015/052714	10-2017-7008807		
13692P/MX	Mexico	Cysteamine for treating yeast and mould infections	Pending	22 Sep 2014	21 Sep 2015	PCT/GB2015/052714	MX/a/2017/003550		
13692P/NZ	New Zealand	Cysteamine for treating yeast and mould infections	Allowed/Accepted	22 Sep 2014	21 Sep 2015	PCT/GB2015/052714	730092		
13692P/RU	Russian Federation	Cysteamine for treating yeast and mould infections	Pending	22 Sep 2014	21 Sep 2015	PCT/GB2015/052714	2017108196		
13692P/SG	Singapore	Cysteamine for treating yeast and mould infections	Pending	22 Sep 2014	21 Sep 2015	PCT/GB2015/052714	11201701648U		

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
13692P/UA	Ukraine	Cysteamine for treating yeast and mould infections	Pending	22 Sep 2014	21 Sep 2015	PCT/GB2015/052714	a 201702256		
13692P/US	USA	Cysteamine for treating yeast and mould infections	Pending	22 Sep 2014	22 Sep 2015	14/860,979			
13692P/USpriority	USA	Cysteamine for treating yeast and mould infections	Abandoned		22 Sep 2014	62/053,523			
13692P/WO	WIPO	Cysteamine for treating yeast and mould infections	Ceased/Mann ed PCT	22 Sep 2014	21 Sep 2015	PCT/GB2015/052714			
13692P/ZA	South Africa	Cysteamine for treating yeast and mould infections	Pending	22 Sep 2014	21 Sep 2015	PCT/GB2015/052714	2017/01330		
13980P/GB	UK	Cystamine	Abandoned		22 Sep 2014	1416716.7			
13980P/US	USA	Cystamine	Abandoned	22 Sep 2014	22 Sep 2015	14/860,970			
13980P/USpriority	USA	Cystamine	Abandoned		22 Sep 2014	62/053,505			
13980P/WO	WIPO	Cystamine	Abandoned	22 Sep 2014	21 Sep 2015	PCT/GB2015/052713			
14380P/GB	UK	Powdered nail medium	Abandoned		22 Jan 2016	1601191.8			
14380P/USpriority	USA	Powdered nail medium	Abandoned		22 Jan 2016	62/286,094			
14832P/AU	Australia	Treatment of Mycobacterium infection	Pending	10 Jun 2015	06 Jun 2016	PCT/GB2016/051662	2016275263		

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
14832P/CA	Canada	Treatment of Mycobacterium infection	Pending	10 Jun 2015	06 Jun 2016	PCT/GB2016/051662	2,988,212		
14832P/EP	EPO	Treatment of Mycobacterium infection	Pending	10 Jun 2015	06 Jun 2016	PCT/GB2016/051662	16732322.9		
14832P/GB	UK	Treatment of Mycobacterium infection	Abandoned		10 Jun 2015	1510077.9			
14832P/IL	Israel	Treatment of Mycobacterium infection	Pending	10 Jun 2015	06 Jun 2016	PCT/GB2016/051662	256162		
14832P/NZ	New Zealand	Treatment of Mycobacterium infection	Pending	10 Jun 2015	06 Jun 2016	PCT/GB2016/051662	738231		
14832P/US	USA	Treatment of Mycobacterium infection	Pending	10 Jun 2015	06 Jun 2016	PCT/GB2016/051662	15/509,466		
14832P/USpriority	USA	Treatment of Mycobacterium infection	Abandoned		10 Jun 2015	62/173,615			
14832P/WO	WIPO	Treatment of Mycobacterium infection	Ceased/Matured PCT	10 Jun 2015	06 Jun 2016	PCT/GB2016/051662			
15413P/GB	UK	Formulation of Lynovex	Abandoned		07 Jun 2016	1609940.0			
15413P/US	USA	Formulation of Lynovex	Pending	07 Jun 2016	06 Jun 2017	15/615,646			

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
15413P/USpriority	USA	Formulation of Lynovex	Abandoned		07 Jun 2016	62/346,969			
15413P/WO	WIPO	Formulation of Lynovex	Pending	07 Jun 2016	06 Jun 2017	PCT/GB2017/051637			
15515P/GB	UK	Reversal of antibiotic resistance using cysteamine	Abandoned		07 Jun 2016	1609921.0			
15515P/GB1	UK	Reversal of antibiotic resistance using cysteamine	Abandoned		16 Dec 2016	1621447.0			
15515P/US	USA	Reversal of antibiotic resistance using cysteamine	Pending	07 Jun 2016	06 Jun 2017	15/615,635			
15515P/USpriority	USA	Reversal of antibiotic resistance using cysteamine	Abandoned		07 Jun 2016	62/346,946			
15515P/WO	WIPO	Reversal of antibiotic resistance using cysteamine	Pending	07 Jun 2016	06 Jun 2017	PCT/GB2017/051625			
15691P/GB	UK	Nebulised formulation	Abandoned		07 Jun 2016	1609925.1			
15691P/US	USA	Nebulised formulation	Pending	07 Jun 2016	05 Jun 2017	15/614,246			
15691P/USpriority	USA	Nebulised formulation	Abandoned		07 Jun 2016	62/346,959			
15691P/WO	WIPO	Nebulised formulation	Pending	07 Jun 2016	05 Jun 2017	PCT/GB2017/051615			

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
17032P/GB	UK	Cysteamine as Neutrophil elastase inhibitor	Abandoned		06 Jun 2017	1708965.7			
17032P/US	USA	Cysteamine as Neutrophil elastase inhibitor	Pending	06 Jun 2017	04 Jun 2018	15/997,000			
17032P/USpriority	USA	Cysteamine as Neutrophil elastase inhibitor	Abandoned		06 Jun 2017	62/515,922			
17032P/WO	WIPO	Cysteamine as Neutrophil elastase inhibitor	Pending	06 Jun 2017	05 Jun 2018	PCT/GB2018/051526			
3213P/EP	EPO	Nail Model	Refused	22 Dec 2009	20 Dec 2010	PCT/GB2010/002313	10803265.7		
3213P/GB	UK	Nail Model	Abandoned		22 Dec 2009	0922403.1			
3213P/US	USA	Nail Model	Abandoned	22 Dec 2009	20 Dec 2010	PCT/GB2010/002313	13/517,230		
3213P/USPriority	USA	Nail Model	Abandoned		23 Dec 2009	61/289911			
3213P/WO	WIPO	Nail Model	Ceased/Matured PCT	22 Dec 2009	20 Dec 2010	PCT/GB2010/002313			
4059P/AU	Australia	Arginine/Phenylalanine Peptides	Granted	31 Mar 2010	30 Mar 2011	PCT/GB2011/000480	2011234252	25 Aug 2016	2011234252
4059P/AU1	Australia	Arginine/Phenylalanine Peptides	Granted	31 Mar 2010	30 Mar 2011	PCT/GB2011/000480	2016208308	03 May 2018	2016208308
4059P/AU2	Australia	Arginine/Phenylalanine Peptides	Pending	31 Mar 2010	30 Mar 2011	PCT/GB2011/000480	2018202201		
4059P/BR	Brazil	Arginine/Phenylalanine Peptides	Pending	31 Mar 2010	30 Mar 2011	PCT/GB2011/000480	BR112012024676		

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
		ine Peptides					3		
4059P/CA	Canada	Arginine/Phenylalanine Peptides	Granted	31 Mar 2010	30 Mar 2011	PCT/GB2011/000480	2797437	07 Nov 2017	2797437
4059P/CN	China	Arginine/Phenylalanine Peptides	Granted	31 Mar 2010	30 Mar 2011	PCT/GB2011/000480	2011800247687	10 May 2017	ZL2011800247687
4059P/EP	EPO	Arginine/Phenylalanine Peptides	Pending	31 Mar 2010	30 Mar 2011	PCT/GB2011/000480	11730384.2		
4059P/GB	UK	Arginine/Phenylalanine Peptides	Abandoned	31 Mar 2010	05 Oct 2010	1016733.6			
4059P/HK	Hong Kong	Arginine/Phenylalanine Peptides	Pending	31 Mar 2010	30 Mar 2011	PCT/GB2011/000480	13103167.6		
4059P/IL	Israel	Arginine/Phenylalanine Peptides	Granted	31 Mar 2010	30 Mar 2011	PCT/GB2011/000480	222027	01 Mar 2017	222027
4059P/IN	India	Arginine/Phenylalanine Peptides	Pending	31 Mar 2010	30 Mar 2011	PCT/GB2011/000480	3215/KOLNP/2012		
4059P/JP	Japan	Arginine/Phenylalanine Peptides	Granted	31 Mar 2010	30 Mar 2011	PCT/GB2011/000480	2013-501928	15 Jul 2016	5969457
4059P/KR	Republic of Korea	Arginine/Phenylalanine Peptides	Pending	31 Mar 2010	30 Mar 2011	PCT/GB2011/000480	10-2012-7028107		
4059P/MX	Mexico	Arginine/Phenylalanine Peptides	Granted	31 Mar 2010	30 Mar 2011	PCT/GB2011/000480	MX/A/2012/011369	27 May 2015	330343
4059P/NZ	New Zealand	Arginine/Phenylalanine Peptides	Granted	31 Mar 2010	30 Mar 2011	PCT/GB2011/000480	603200	04 Jun 2014	603200
4059P/NZ1	New Zealand	Arginine/Phenylalanine Peptides	Granted	01 Mar 2010	30 Mar 2011	PCT/GB2011/000480	618571	28 May 2015	618571
4059P/RU	Russian	Arginine/Phenylalanine Peptides	Granted	31 Mar 2010	30 Mar 2011	PCT/GB2011/000480	2012145756	10 Jul 2016	2590706

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
	Federation	ine Peptides							
4059P/SG	Singapore	Arginine/Phenylalanine Peptides	Granted	31 Mar 2010	30 Mar 2011	PCT/GB2011/000480	SC201206926-6	21 May 2015	184138
4059P/UA	Ukraine	Arginine/Phenylalanine Peptides	Pending	31 Mar 2010	30 Mar 2011	PCT/GB2011/000480	A2012 12139		
4059P/US	USA	Arginine/Phenylalanine Peptides	Granted	31 Mar 2010	30 Mar 2011	PCT/GB2011/000480	13/638,436	02 Dec 2014	8901071
4059P/USpriority	USA	Arginine/Phenylalanine Peptides	Abandoned		05 Oct 2010	61/390,081			
4059P/WO	WIPO	Arginine/Phenylalanine Peptides	Ceased/Matured PCT	31 Mar 2010	30 Mar 2011	PCT/GB2011/000480			
4059P/ZA	South Africa	Arginine/Phenylalanine Peptides	Granted	31 Mar 2010	30 Mar 2011	PCT/GB2011/000480	2012/08173	31 Jul 2013	2012/08173
4393P/AU	Australia	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	2011343012	18 May 2017	2011343012
4393P/AU1	Australia	Cysteamine and Antibiotics	Pending	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	2017201670		
4393P/BR	Brazil	Cysteamine and Antibiotics	Pending	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	BR 11 2013 015010 6		
4393P/CA	Canada	Cysteamine and Antibiotics	Pending	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	2821032		
4393P/CN	China	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	2011800640110	09 Nov 2016	ZL2011800640110
4393P/EP	EPO	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EP1	EPO	Cysteamine and Antibiotics	Pending	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	15192845.4		

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
		Antibiotics							
4393P/EPAL	Albania	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EPAT	Austria	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EPBE	Belgium	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EPBG	Bulgaria	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EPCH	Switzerland	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EP CY	Cyprus	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EP CZ	Czechia	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EP DE	Germany	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EP DK	Denmark	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EP EE	Estonia	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EP ES	Spain	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EP FI	Finland	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EP FR	France	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
		Antibiotics							
4393P/EPGB	UK	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EPGR	Greece	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EPHR	Croatia	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EPHU	Hungary	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EPIE	Ireland	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EPIS	Iceland	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EPIT	Italy	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EPLT	Lithuania	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EPLU	Luxembourg	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EPLV	Latvia	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EPMC	Monaco	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EPMK	Macedonia	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EPMT	Malta	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
		Antibiotics							
4393P/EPNL	Netherlands	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EPNO	Norway	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EPPL	Poland	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EPPT	Portugal	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EPRO	Romania	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EPRS	Serbia	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EPSE	Sweden	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EP SI	Slovenia	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EP SK	Slovakia	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EP SM	San Marino	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/EP TR	Turkey	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	11808253.6	10 Feb 2016	EP2651419
4393P/GB	UK	Cysteamine and Antibiotics	Abandoned		14 Dec 2010	1021186.0			
4393P/HK	Hong Kong	Cysteamine and	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	13112496.9	20 Jan 2017	1185015B

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
		Antibiotics							
4393P/HK1	Hong Kong	Cysteamine and Antibiotics	Pending	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	16109088.6		
4393P/IL	Israel	Cysteamine and Antibiotics	Pending	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	226879		
4393P/IN	India	Cysteamine and Antibiotics	Pending	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	2163/KOLNP/2013		
4393P/JP	Japan	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	2013-543872	08 Jul 2016	5964854
4393P/JP1	Japan	Cysteamine and Antibiotics	Pending	14 Dec 2010			2016-129761		
4393P/KR	Republic of Korea	Cysteamine and Antibiotics	Pending	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	10-2013-7017966		
4393P/MX	Mexico	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	MX/A/2013/006873	27 Mar 2017	346664
4393P/MX1	Mexico	Cysteamine and Antibiotics	Pending	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	MX/A/2017/004006		
4393P/NZ	New Zealand	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	613076	25 Mar 2015	613076
4393P/RU	Russian Federation	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	2013131391	10 Jan 2017	2607660
4393P/RU1	Russian Federation	Cysteamine and Antibiotics	Pending	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	2016151115		
4393P/SG	Singapore	Cysteamine and Antibiotics	Abandoned	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	201304561-2		
4393P/SG1	Singapore	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	10201510095Y	24 Apr 2017	10201510095Y

Our ref	Country	Title	Status	Priority Date	Filing Date	Filing No	Nat Entry Filing No	Grant Date	Grant No
		Antibiotics							
4393P/SG2	Singapore	Cysteamine and Antibiotics	Pending	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	10201703290U		
4393P/UA	Ukraine	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	A 201308670	26 Jun 2017	114470
4393P/UA 1	Ukraine	Cysteamine and Antibiotics	Pending	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	A 201700511		
4393P/US	USA	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	13/486,778	10 Oct 2017	9,782,423
4393P/US1	USA	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	14/460,953	14 Jun 2016	9364491
4393P/US2	USA	Cysteamine and Antibiotics	Pending	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	15/041,393		
4393P/USpriority	USA	Cysteamine and Antibiotics	Abandoned		14 Dec 2010	61/423,000			
4393P/WO	WIPO	Cysteamine and Antibiotics	Ceased/Matured PCT	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721			
4393P/ZA	South Africa	Cysteamine and Antibiotics	Granted	14 Dec 2010	14 Dec 2011	PCT/GB2011/001721	2013/05207	26 Mar 2014	2013/05207

SIGNATURE PAGE

EXECUTED as a DEED
by NOVABIOTICS LIMITED
acting by a director in the presence of:

)
)
) Director

Witness Signature.....

Witness Name..... PAUL MCINTOSH

Witness Address..... 21 BAIRD WAY

..... MONTROSE, DD10 9DU

Witness Occupation..... HEAD OF ADMIN

EXECUTED as a **DEED**

by **BARWELL PLC**

acting by ALEXANDER C. C. MACKIE,

an authorised signatory, in the presence of:

.....
Authorised Signatory

Witness Signature. 

Witness Name ASHLEIGH HAGGARTY

Witness Address c/o 20 RENFIELD STREET

GLASGOW G2 5AP

Witness Occupation INVESTMENT EXECUTIVE